The US Supreme Court has agreed to delve into a contentious patent dispute between Sandoz and Amgen over how quickly lower-cost biosimilar drugs can make it to market.
This has huge implications for how all biosimilars are marketed and priced, because these drugs represent some $44 billion in health care cost savings through 2024. Biosimilars are expected to be priced at 10 to 30 percent less than their branded counterparts.
About the Author Reprints
